Also, the results of multivariate Cox regression analysis showed that the high expression of CHRNA9 (P < 0.05) and clinical characteristics such as WHO grade (P < 0.01), IDH status (P < 0.001), Age (P < 0.001), and primary therapy outcome (P < 0.01) were all closely related to the poor prognosis of glioma patients. This evidence concerns the gene CHRNA9 and central nervous system cancer.